The Achilles' Heel of Private Health Insurance: New Manual Therapy Guidelines Spark Intense Debate

As new guidelines emerge for manual therapy—long identified as a primary driver of deficits in South Korea's private health insurance sector—tension is mounting among insurers, medical institutions, and policyholders. While the revision aims to curb overtreatment and restore fiscal soundness, it faces fierce backlash over potential infringements on patients' right to treatment and clinical autonomy, raising fundamental questions at the intersection of private finance and public healthcare.

The Grey Zone of Medical Consumption: Accumulated Conflicts Over Manual Therapy

Private health insurance in South Korea has become so ubiquitous that it is often referred to as the 'second national health insurance.' However, the rapid expansion of non-reimbursable medical items has led to deteriorating loss ratios for insurers and rising premiums for policyholders. According to a report by Maekyung, the recently proposed guidelines for manual therapy represent a desperate measure by regulators and the industry to address these deep-seated conflicts.

Manual therapy, a prominent non-reimbursable treatment where physical therapists manually realign the spine or joints under a doctor's prescription, has long been blamed for insurance payout leaks. In the absence of clear clinical standards, a combination of overtreatment by certain medical institutions and moral hazard among patients has ballooned expenditures. The current debate over guideline revision is not merely about cost control; it is an attempt to redefine the boundary between private financial contracts and public healthcare services.

Core of the New Guidelines: Standardization vs. Excessive Regulation

Tightening Treatment Limits and Medical Opinion Requirements

The crux of the new guidelines lies in strengthening the criteria for proving the clinical necessity of manual therapy. While patients could previously claim insurance payouts for an almost unlimited number of sessions based on subjective medical opinions, the new framework proposes clear caps on treatment frequency. Beyond these limits, policyholders must submit objective diagnostic results or detailed medical justifications to qualify for payouts.

Clashing Perspectives: Insurers vs. Healthcare Providers

The insurance industry has welcomed the move, expecting it to curb unnecessary treatments, improve the chronic deficit structure of private health insurance, and ultimately ease the premium burden on honest policyholders. Conversely, the medical community and patient advocacy groups are raising strong objections. They argue that applying uniform standards ignores individual patient variations, infringes upon doctors' clinical autonomy, and deprives patients of essential care.

Macroeconomic Implications at the Intersection of Finance and Healthcare

While the revised guidelines may improve insurers' loss ratios in the short term, they risk causing a contraction in the broader non-reimbursable medical market or triggering a balloon effect, where demand shifts to other unregulated treatments. This highlights the need for close coordination between financial and health authorities. If regulatory measures are not finely tuned, they may inadvertently harm patients who genuinely require intensive therapy.

Ultimately, this debate is a necessary growing pain in establishing a sustainable healthcare finance ecosystem. To establish a clear investment direction amid complex market conditions, we recommend comprehensively leveraging FireMarkets' in-depth analysis content and fundamental on-chain data.